Millennium Management
RNAC icon

Millennium Management’s Cartesian Therapeutics RNAC Stock Holding History

Millennium Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,667
Closed -$905K – 7021
2021
Q1 		$905K Buy
+6,667
New +$828K ﹤0.01% 4314

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Millennium Management's RNAC Position: Q1 2026 in Review

Millennium Management increased its Cartesian Therapeutics (RNAC) stake by 73% in Q1 2026, buying an estimated $855K and bringing the position to 284,317 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

Millennium Management first reported a position in RNAC in Q2 2016 and has held it in 31 quarters since. The position peaked at $7.95M in Q3 2022. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Millennium Management held 284,317 shares of Cartesian Therapeutics worth $1.75M as of Q1 2026.
  • Millennium Management bought 119,951 Cartesian Therapeutics shares in Q1 2026, an estimated $855K.
  • Cartesian Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3995 holding.
  • Millennium Management first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 31 quarters since.
  • Millennium Management's Cartesian Therapeutics position peaked at $7.95M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.